Literature DB >> 2052529

The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat.

H W Frijlink1, E J Franssen, A C Eissens, R Oosting, C F Lerk, D K Meijer.   

Abstract

Naproxen and flurbiprofen form complexes with hydroxypropyl-beta-cyclodextrin; with stability constants of 2207 and 12515 M-1, respectively. However, only small fractions of the drug remain complexed when the drug-cyclodextrin complex is added to plasma in vitro. This result can be explained by albumin effectively competing with cyclodextrin for drug binding and by the simultaneous displacement of the drug from cyclodextrins by plasma cholesterol. Naproxen and flurbiprofen were administered intravenously to rats as cyclodextrin complexes. The disposition in the body of naproxen was not significantly altered by the complexation. This indicates that immediately after administration all drug is removed from the cyclodextrin complex. However, the initial distribution of flurbiprofen was changed upon complexation. Drug concentrations in liver, brain, kidney, and spleen were increased, indicating that hydroxypropyl-beta-cyclodextrin may improve the presentation of the flurbiprofen to biomembranes, as compared with plasma proteins. The effect was transient; 60 min after injection the differences in tissue concentration compared with controls were dissipated. Finally, the importance of protein binding in determining the mode of interaction of cyclodextrins on drug disposition is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2052529     DOI: 10.1023/a:1015857902238

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Characterization of drug distribution and binding competition by two-chamber and multi-chamber distribution dialysis.

Authors:  M H Bickel; R M Raaflaub; M Hellmüller; E J Stauffer
Journal:  J Pharm Sci       Date:  1987-01       Impact factor: 3.534

2.  Effects of beta- and gamma-cyclodextrins on the pharmacokinetic behavior of prednisolone after intravenous and intramuscular administrations to rabbits.

Authors:  K Arimori; K Uekama
Journal:  J Pharmacobiodyn       Date:  1987-08

Review 3.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

Review 4.  Inclusion compounds of cyclodextrins.

Authors:  F Cramer; H Hettler
Journal:  Naturwissenschaften       Date:  1967

5.  The effect of parenterally administered cyclodextrins on cholesterol levels in the rat.

Authors:  H W Frijlink; A C Eissens; N R Hefting; K Poelstra; C F Lerk; D K Meijer
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

6.  Effects of cyclodextrins on chlorpromazine-induced haemolysis and central nervous system responses.

Authors:  K Uekama; T Irie; M Sunada; M Otagiri; K Iwasaki; Y Okano; T Miyata; Y Kasé
Journal:  J Pharm Pharmacol       Date:  1981-11       Impact factor: 3.765

Review 7.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

8.  Aggregation of amphotericin B in the presence of gamma-cyclodextrin.

Authors:  M Kajtár; M Vikmon; E Morlin; J Szejtli
Journal:  Biopolymers       Date:  1989-09       Impact factor: 2.505

9.  Improved delivery through biological membranes. XXXL: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins.

Authors:  M E Brewster; K S Estes; T Loftsson; R Perchalski; H Derendorf; G Mullersman; N Bodor
Journal:  J Pharm Sci       Date:  1988-11       Impact factor: 3.534

10.  Testosterone in a cyclodextrin-containing formulation: behavioral and physiological effects of episode-like pulses in rats.

Authors:  G T Taylor; J Weiss; J Pitha
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

View more
  6 in total

Review 1.  Cyclodextrins: their future in drug formulation and delivery.

Authors:  V J Stella; R A Rajewski
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

2.  Self-assembled polymeric micellar nanoparticles as nanocarriers for poorly soluble anticancer drug ethaselen.

Authors:  Xinru Li; Zhuoli Yang; Kewei Yang; Yanxia Zhou; Xingwei Chen; Yanhui Zhang; Fei Wang; Yan Liu; Lijun Ren
Journal:  Nanoscale Res Lett       Date:  2009-09-16       Impact factor: 4.703

3.  Effect of cyclodextrins on protein binding of drugs: the diflunisal/hydroxypropyl-beta-cyclodextrin model case.

Authors:  E E Sideris; M A Koupparis; P E Macheras
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

4.  α-Cyclodextrin dimer complexes of dopamine and levodopa derivatives to assess drug delivery to the central nervous system: ADME and molecular docking studies.

Authors:  Sergey Shityakov; Jens Broscheit; Carola Förster
Journal:  Int J Nanomedicine       Date:  2012-06-27

5.  A cyclodextrin formulation to improve use of the anesthetic tribromoethanol (Avertin(®)).

Authors:  Arlene McDowell; Jessica A Fothergill; Azeem Khan; Natalie J Medlicott
Journal:  J Pharm Bioallied Sci       Date:  2014-01

6.  Antiproliferative effect of methyl-beta-cyclodextrin in vitro and in human tumour xenografted athymic nude mice.

Authors:  P Y Grosse; F Bressolle; F Pinguet
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.